HC Wainwright & Co. Reiterates Neutral on Aclaris Therapeutics
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Neutral rating on Aclaris Therapeutics, indicating no change in their outlook for the company.
September 17, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating on Aclaris Therapeutics, suggesting no change in their outlook for the company's stock.
The reiteration of a Neutral rating by HC Wainwright & Co. suggests that there is no new information or change in the analyst's outlook on Aclaris Therapeutics. This typically indicates a stable view on the stock, with no expected short-term price movement based on this news alone.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100